PolymarketVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibradoProbabilidade implícita atualSim 6%
Qualidade do mercado
56 / 100
Qualidade médiaVolume 24h
2,8 €
Liquidez
38,1 mil €
Alta liquidezCompra / Venda
5.0% / 6.0%
Spread
20.0%
Spread amploDados do mercado
Atualizado há 16 minutos
4/05/26, 14:4131/12/26, 0:00
Tendências
Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro
Resultado escolhido
Yes6%
Grandes negociações
$1.3k95.0%POLYMARKETNo0x0e7b…eba3há 24 dias
POLYMARKETNo0x0e7b…eba3há 24 diasTendência de volume
$32 de jul.24d de dados26 de jul.
Mercados Relacionados
Will artificial blood be used to treat a patient by the end of 2026?
439,5 €Sim: 9.7%MANIFOLD MARKETS
MANIFOLD MARKETSDo short sleeper genes exist, and do they accelerate repair proccesses?
351,6 €Sim: 39.7%MANIFOLD MARKETS
MANIFOLD MARKETSWill "The worthlessness of vitamin D is mildly exag..." make the top fifty posts in LessWrong's 2026 Annual Review?
229,6 €Sim: 12%MANIFOLD MARKETS
MANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?
0 €before September: 10%
KALSHI
KALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?
56,1 €before 2027: 78%KALSHI
KALSHI
Will there be a year without polio before 2030?
0 €Sim: 11%KALSHI
KALSHIAtivos nestes tópicos
Notícias Relacionadas
Galaxy Digital opens $5M fund for Bitcoin quantum security researchCrypto News
Claude's Fable 5 just solved an 87-year-old math problem, and it matters for bitcoinCoindesk
Google DeepMind, Isomorphic Labs Unveil AI-Powered Bioresilience PlanBlockchain.News
NVIDIA's Ising Decoder Slashes Color Code Errors 300xBlockchain.News
NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.NewsNvidia NVSHMEM Boosts GROMACS GPU Scaling for Molecular DynamicsBlockchain.NewsRegras
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S.
- Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.